vs 6,662 other HR bills in the 112th — cohort avg 39d
Summary
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
Lobbying filings that explicitly cite this bill (20)
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Legislation in the 112th
H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th
S. 847, the Safe Chemicals Act of 2011
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 2359, the Safe Cosmetics Act of 2011
The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
H.R.4395, the Cosmetic Safety Amendments Act of 2012
The Breast Cancer Fund opposes this legislation as it would further weaken the FDAs ability to regulate the safety of cosmetics.
H.R. 4262, the Cosmetics Safety Enhancement Act of 2012
The Breast Cancer Fund opposes this legislation as it is not strong enough to effectively regulate the safety of cosmetics.
H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and
H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011
The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer.
H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011.
The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely.
H.R. 3067: Accelerating the End of Breast Cancer Act of 2011.
The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner.
S. 3237, the Accelerating the End of Breast Cancer Act of 2012.
The Breast Cancer Fund supports this legislation as it would increase focus on research to prevent, treat, and end breast cancer.
House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program, opposing appropriations riders limiting the work of the National Toxicology Program's Report on Carcinogens, and increasing support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally.
Presidents Cancer Panel Report
The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment.
P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation.
P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
Client expense: Not reported · Firm income: $30,000
Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE
Cited source text, amounts, lobbyists, and targets
Legislation in the 112th
H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th
S. 847, the Safe Chemicals Act of 2011
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 2359, the Safe Cosmetics Act of 2011
The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
H.R.4395, the Cosmetic Safety Amendments Act of 2012
The Breast Cancer Fund opposes this legislation as it would further weaken the FDAs ability to regulate the safety of cosmetics.
H.R. 4262, the Cosmetics Safety Enhancement Act of 2012
The Breast Cancer Fund opposes this legislation as it is not strong enough to effectively regulate the safety of cosmetics.
H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and
H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011
The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer.
H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011.
The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely.
H.R. 3067: Accelerating the End of Breast Cancer Act of 2011.
The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner.
S. 3237, the Accelerating the End of Breast Cancer Act of 2012.
The Breast Cancer Fund supports this legislation as it would increase focus on research to prevent, treat, and end breast cancer.
House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program, opposing appropriations riders limiting the work of the National Toxicology Program's Report on Carcinogens, and increasing support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally.
Presidents Cancer Panel Report
The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment.
P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation.
P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
Client expense: Not reported · Firm income: $30,000
Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), Office of Science & Technology Policy (OSTP), SENATE
Cited source text, amounts, lobbyists, and targets
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions
and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional
Directed Medical Research Programs.
Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research,
cancer screening programs and Congressional directed medical research programs.
S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013,
primarily matters related to funding of cancer research and CDC cancer prevention and control programs.
H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing
notification requirements to mitigate drug shortages.
H.R. 3839, Drug Shortage Prevention Act of 2012.
H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011.
H.R.3102, Breast Density and Mammography Reporting Act of 2011.
H.R.3067, Accelerating the End of Breast Cancer Act of 2011.
H.R.3705, Comprehensive Cancer Care Improvement Act of 2011.
H.R.2746, Cancer Drug Coverage Parity Act of 2011.
H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply
chain.
H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy.
S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying
and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions.
S.2236, Advancing Breakthrough Therapies for Patients Act of 2012.
Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug
shortages, drug approval and patient access.
H.R. 4209, Patients' Access to Treatments Act of 2012.
H.R. 5937, Breast Cancer Patient Education Act of 2012.
H.R. 6157, Patient Centered Quality Care for Life Act of 2012
Client expense: $25,001 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Cited source text, amounts, lobbyists, and targets
Legislation in the 112th
H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th
S. 847, the Safe Chemicals Act of 2011
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 2359, the Safe Cosmetics Act of 2011
The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
H.R.4395, the Cosmetic Safety Amendments Act of 2012
The Breast Cancer Fund opposes this legislation as it would further weaken the FDAs ability to regulate the safety of cosmetics.
H.R. 4262, the Cosmetics Safety Enhancement Act of 2012
The Breast Cancer Fund opposes this legislation as it is not strong enough to effectively regulate the safety of cosmetics.
H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and
H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011
The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer.
H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011.
The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely.
H.R. 3067: Accelerating the End of Breast Cancer Act of 2011.
The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner.
S. 3237, the Accelerating the End of Breast Cancer Act of 2012.
The Breast Cancer Fund supports this legislation as it would increase focus on research to prevent, treat, and end breast cancer.
House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research. Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally.
Presidents Cancer Panel Report
The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment.
P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation.
P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
Cited source text, amounts, lobbyists, and targets
See addendum page. Food and Drug Administration Safety and Innovation Act (S.3187): lobbied in support of the drug shortages bill included in S.3187.
Lobbied on changes to the National Childrens Study recruitment procedures and to ask for Congressional review.
Lobbied in support of Accelerating the End of Breast Cancer Act of 2011 (H.R. 3067).
Lobbied in opposition to Registered Nurse Safe Staffing Act of 2011 (H.R. 876).
Reviewed Home Health Care Planning Improvement Act of 2011 (H.R. 2267). CU is neutral on this bill.
Reviewed Medicare Cost Contract Extension Act of 2011 (H.R. 2770). CU is neutral on this bill.
Reviewed Health Care Cost Reduction Act of 2012 (H.R. 436) and the Protect Medical Innovation Act of 2011 contained therein. CU is neutral on this bill.
Reviewed the Quality Health Care Coalition Act of 2011 (H.R. 1409). CU is neutral on this bill.
Client expense: $124,204 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs.
Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs.
S.3295, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2013, primarily matters related to funding of cancer research and CDC cancer prevention and control programs.
H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages.
H.R. 3839, Drug Shortage Prevention Act of 2012.
H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011.
H.R.3102, Breast Density and Mammography Reporting Act of 2011.
H.R.3067, Accelerating the End of Breast Cancer Act of 2011.
H.R.3705, Comprehensive Cancer Care Improvement Act of 2011.
H.R.2746, Cancer Drug Coverage Parity Act of 2011.
H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain.
H.R.3699, Research Works Act, primarily matters related to opposing it in order to protect the NIH Public Access Policy.
S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions.
S.2236, Advancing Breakthrough Therapies for Patients Act of 2012.
Pub. Law No. 112-144, Food and Drug Administration Safety and Innovation Act of 2012, primarily matters related to drug shortages, drug approval and patient access.
H.R. 4209, Patients' Access to Treatments Act of 2012.
H.R. 5937, Breast Cancer Patient Education Act of 2012.
Cited source text, amounts, lobbyists, and targets
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions and provisions on breast health education, research and clinical trials. (Continued on Addendum) H.R.3070/S.1599, Department of Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs.
H.R.2219, Department of Defense Appropriations Act, primarily matters related to appropriations for Congressional Directed Medical Research Programs.
Pub. Law No. 112-74, Consolidated Appropriations Act, 2012, primarily matters related to appropriations for cancer research, cancer screening programs and Congressional directed medical research programs.
Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and CDC cancer prevention and control programs.
H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to establishing notification requirements to mitigate drug shortages.
H.R. 3839, Drug Shortage Prevention Act of 2012.
H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011.
H.R.3102, Breast Density and Mammography Reporting Act of 2011.
H.R.3067, Accelerating the End of Breast Cancer Act of 2011.
H.R.3705, Comprehensive Cancer Care Improvement Act of 2011.
H.R.2746, Cancer Drug Coverage Parity Act of 2011.
H.R.1483, Drug Safety Enhancement Act of 2011, primarily matters related to ensuring the safety and quality of the drug supply chain.
H.R.3699, Research Works Act, primarily matters related to opposing an order to protect the NIH Public Access Policy.
S.2113, Transforming the Regulatory Environment to Accelerate Access to Treatments, primarily matters related to codifying and clarifying FDA authority to expedite approval of new treatments for life-threatening conditions.
S.2236, Advancing Breakthrough Therapies for Patients Act of 2012.
Support of draft congressional resolution for reauthorization of the Prescription Drug User Fee Act (PDUFA), primarily matters related to drug shortages, drug approval and patient access.
Cited source text, amounts, lobbyists, and targets
Legislation in the 112th
H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th
S. 847, the Safe Chemicals Act of 2011
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 2359, the Safe Cosmetics Act of 2011
The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and
H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011
The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer.
H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011.
The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely.
H.R. 3067: Accelerating the End of Breast Cancer Act of 2011.
The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner.
House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research.
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report
The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment.
P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation.
P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
Cited source text, amounts, lobbyists, and targets
Funding for the DOD peer-reviewed Breast Cancer Research Program; Enactment of H.R. 3067, Accelerating the End of Breast Cancer Act; and issues related to the Breast Cancer Deadline 2020 goal of ending breast cancer by January 1, 2020.
Client expense: $259,616 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense Advanced Research Projects Agency (DARPA), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
Cited source text, amounts, lobbyists, and targets
Funding for the DOD peer-reviewed Breast Cancer Research Program; Guaranteed Access to Quality Care for All; Breast and Cervical Cancer Treatment Program; Health Care Reform; Enactment of H.R. 3067, Accelerating the End of Breast Cancer Act; and issues related to the Breast Cancer Deadline 2020 goal of ending breast cancer by January 1, 2020.
Client expense: $259,616 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense Advanced Research Projects Agency (DARPA), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
Cited source text, amounts, lobbyists, and targets
Legislation in the 112th
H.R. 432, the Ban Poisonous Additives Act of 2011( related Senate Bill, S. 136) The Breast Cancer Fund supports this legislation because bisphenol-A has been linked to increased rates of cancer, as well as other significant health problems. The Breast Cancer Fund has been meeting with staff from various offices to encourage co-sponsorship and eventual passage of this bill. Continued: Legislation in the 112th
S. 847, the Safe Chemicals Act of 2011
The Breast Cancer Fund supports this legislation because it would mandate the testing of chemicals for their health risks, including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
H.R. 2359, the Safe Cosmetics Act of 2011
The Breast Cancer Fund supports this legislation to reform the FDA's regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
H.R. 2521, the Endocrine-Disrupting Chemicals Exposure Elimination act of 2011 (Senate version S. 1361) and
H.R. 553 Endocrine Disruptor Screening Enhancement Act of 2011
The Breast Cancer Fund supported this legislation as it would increase the coordination and resources dedicated to research on endocrine disrupting substances, an important link to increased risk of lifetime incidence of breast cancer.
H.R. 1939: Enhancing CPSC Authority and Discretion Act of 2011.
The Breast Cancer Fund lobbied for a provision that ensures that phthalates, when necessary in the manufacture of children's toys, are only used safely.
H.R. 3067: Accelerating the End of Breast Cancer Act of 2011.
The Breast Cancer Fund supported this legislation as it would increase focus on research to prevent, treat, and end breast caner.
House and Senate Appropriations - The Breast Cancer Fund contacted House and Senate offices about increasing federal funding for state biomonitoring programs through the CDC grants program as well as support for health tracking and NIEHS programs related to breast cancer research.
Future Legislative Proposals:
The Breast Cancer Fund continues to meet with staff from various House and Senate offices to draft legislation to reform the FDAs regulation of cosmetic ingredients based on mounting evidence that several ingredients of common cosmetic products have been linked to negative environmental health impacts, including breast cancer.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would compel manufacturers to provide complete and accurate product labeling of chemicals used in consumer products. Such labeling is a critical step in removing carcinogenic, and otherwise hazardous, materials from consumer products.
The Breast Cancer Fund supports ongoing efforts to reintroduce legislation that would mandate the testing of chemicals for their health risks- including potentially hazardous, cancer-causing chemicals currently being used in a variety of consumer products.
Regulation and Legislative Intent:
FDA Advocacy
In addition to meeting with Congressional staff on the matter of bisphenol-A (BPA), The Breast Cancer Fund has also met with Deputy Commissioner Josh Sharfstein and additional members of the FDA management team concerning the FDAs ongoing review of BPA, upcoming cosmetics legislation, and the FDAs transparency policies more generally. Presidents Cancer Panel Report
The Breast Cancer Fund communicated with staff in the Executive Office of the President and the Office of Science and Technology Policy regarding the report and recommendations of the President's Cancer Panel, and continues to encourage ongoing efforts by the Executive Branch to raise awareness about breast cancer risk, prevention, and the environment.
P.L. 110-314 - The Consumer Product Safety Commission Inprovement Act
The Breast Cancer Fund lobbied in support of the provision that bans the use of phthalates in the manufacture of children's toys. We are now monitoring implementation of this law; working on preserving the law's phthalates provision through the legislative and regulatory process; and are submitting public comments at various stages of the law's implementation.
P.L. 110-354 - Breast Cancer and Environmental Research Act of 2008
This law authorizes the Director of the National Institute of Environmental Health Sciences to make grants for the development and operation of research centers regarding environmental factors that may be related to the etiology of breast cancer. The Breast Cancer Fund was not actively involved in passage of the bill apart from coalition support but has since met with authors to discuss implementation and the appointment process to the community panel that will oversee the grant process.
Cited source text, amounts, lobbyists, and targets
Implementation of Pub. Law No. 111-148, the Patient Protection and Affordable Care Act, primarily patient protection provisions, provisions on breast health education and postal provision. (Continued on Addendum) H.R.3070/S.1599, Departments of Labor, Health and Human Services, Education, and Related Agencies Appropriations Act, 2012, primarily matters related to appropriations for cancer research and cancer screening programs.
H.R.2219, Department of Defense Appropriations Act, 2012, primarily matters related to appropriations for Congressional Directed Medical Research Programs.
Pub. Law No. 112-25, the Budget Control Act of 2011, primarily matters related to funding of cancer research and breast cancer programs.
H.R.466/S. 384, Breast Cancer Research Stamp Reauthorization Act.
H.R.2245/S.296, Preserving Access to Life-Saving Medications Act of 2011, primarily matters related to cancer treatments.
H.R.2499, Lymphedema Diagnosis and Treatment Cost-Saving Act of 2011.
H.R.3613, Part D Beneficiary Appeals Fairness Act, primarily matters related to specialty tiers of prescription drugs.
H.R.3102, Breast Density and Mammography Reporting Act of 2011.
H.R.3067, Accelerating the End of Breast Cancer Act of 2011.
H.R.3705, Comprehensive Cancer Care Improvement Act of 2011.
H.R.2746, Cancer Drug Coverage Parity Act of 2011.
H.R.111, Breast Cancer Patient Protection Act of 2011.
Client expense: $160,000 · Firm income: Not reported
Cited source text, amounts, lobbyists, and targets
Funding for the DOD peer reviewed Breast Cancer Research Program; Enactment of H.R. 3067, Accelerating the End of Breast Cancer Act; and issues related to Breast Cancer Deadline goal of ending breast cancer by January 1, 2020.
Client expense: $52,939 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense Advanced Research Projects Agency (DARPA), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
Cited source text, amounts, lobbyists, and targets
Funding for the DOD peer-reviewed Breast Cancer Research Program; Guaranteed Access to Quality Care for All; Breast and Cervical Cancer Treatment Program; Health Care Reform; Enactment of H.R. 3067, Accelerating the End of Breast Cancer Act; and issues related to Breast Cancer Deadline goal of ending breast cancer by January 1, 2020.
Client expense: $52,939 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense Advanced Research Projects Agency (DARPA), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE, White House Office
Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Client expense: $140,000 · Firm income: Not reported
Government targets: Centers For Disease Control & Prevention (CDC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), SENATE
Client expense: Not reported · Firm income: $30,000
Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE
Client expense: Not reported · Firm income: $30,000
Government targets: Consumer Product Safety Commission (CPSC), Environmental Protection Agency (EPA), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Institutes of Health (NIH), Office of Management & Budget (OMB), SENATE